MS news articles for December 2000
Commission Further Research on MS Drugs
NICE 2000/ 052
Issued: 22 December
NICE is extending
the timeline for its appraisal of two drugs ; the beta interferons and
glatiramer acetate - used in the treatment of multiple sclerosis, to enable
further research to be undertaken on their cost effectiveness.
NICE Chief Executive
Andrew Dillon said today;During our appraisal we have considered evidence
that included economic models supplied by manufacturers and independent
researchers, including data not previously submitted. The models are used
to inform our judgement on the cost effectiveness of these drugs.
We have looked carefully
at these models and whilst it’s clear that considerable effort has been
put into their development, detailed examination has raised a number of
issues that the Institute’s Appraisal Committee, using the information
available, has been unable to resolve. The evidence relating to the cost
effectiveness of these medicines is critically important in this appraisal.
The Institute has therefore decided to commission further economic modelling
on the beta interferons and glatiramer acetate. The process of specifying,
commissioning and evaluating this new research will be transparent. The
results will be published in full and consultees in the appraisal will
have the opportunity to comment on it. ;
Notes for Editors
The commissioning, construction
and evaluation of the new modelling will take some months and therefore
the timeline for the appraisal process for both medicines will be extended.
The Institute anticipates
that the Appraisal Committee will reconsider the evidence, which will consist
of the new modelling and any other new evidence available at the time,
in July 2001.
The Institute has notified
all consultees of this course of action.
Although the Institute
accepts that its guidance will now be delayed, it considers that this action
is in the best interests of people with MS and those who care for them.
It is of the utmost importance that the Institute’s guidance is both evidence-based
and seen to be fair by those effected by it. Until the Institute’s appraisal
is complete, NHS organisations will wish to operate in accordance with
NHS Guidance that states they should continue with their own local arrangements.
[HSC (99) 176].
The Institute will proceed
quickly and its Research and Development Committee will convene as early
as possible in January. Its first step will be to consider and agree the
process and timetable for commissioning the new model. The outcome of this
meeting will be reported to consultees and will be posted on the Institute’s
web site. Progress reports will be similarly reported.
This decision has been
taken by the Institute following the Appraisal Committee meeting on December
13th 2000. The Appraisal Committee considered the original evidence in
light of the appeal panel’s decision, in addition they considered some
new evidence, (including a new economic model submitted as commercial in
confidence by Schering) and heard again from the groups that represent
people with MS and their carers. The groups were the MS Society and the
MS Research Trust and their representatives included people with MS.